# DSIP Dosage in Research: The Doses, Routes & Half-Life Studied > DSIP dosage in the research record: 25 nmol/kg intravenous in human sleep studies, 120 nmol/kg subcutaneous in cats, a plasma half-life of only minutes. Research context only — no human dosing guidance. A research-context summary of the doses recorded in the literature — not a protocol, not guidance. ## Start here This page describes the DSIP doses used in published studies — it is not a how-to, and it gives no human dosing advice. The number that recurs in human research is 25 nmol/kg given by vein (intravenously); that is the dose behind the small 1980s insomnia studies [2]. Animal studies used different amounts and routes: 120 nmol/kg under the skin in cats [10], microgram amounts infused into the brain in rats, and a Deltaran preparation at about 100 µg/kg in mice [5]. One fact shapes everything: in animals, DSIP disappears from the blood in only minutes, broken down by enzymes — so its short half-life is part of why dosing it is tricky. There is no validated human pharmacokinetic profile and no approved product, so no standard dose exists. Everything below is research context, stated in third person. ## DSIP dosage Across the literature, DSIP dosage clusters by species and goal. In human sleep and clinical research, 25 nmol/kg by intravenous infusion is the most frequently used dose, and it is the one tied to the reported improvements in disturbed sleep [2]. In rat growth-hormone studies, doses ran from roughly 0.1 to 10 micrograms infused into the brain (intracerebroventricular), with a minimal effective amount near 0.1 microgram. In cat sleep studies, 120 nmol/kg was given subcutaneously [10]. A complicating feature reported in characterization work is a parabolic dose-response — effect rising then falling with dose — so a higher amount is not reliably more active than an intermediate one [11]. None of these figures translates into a human protocol. ## DSIP peptide dosage Framing DSIP peptide dosage requires separating route from amount, because the two are coupled in this literature. The brain-infusion (intracerebroventricular) rodent doses are tiny — fractions of a microgram — because the peptide is placed directly where it acts. Peripheral doses (intravenous in humans, subcutaneous in cats) are larger to account for rapid breakdown before the peptide can reach the central nervous system. Neuroprotection studies in rats used 120 micrograms/kg intranasally, and the mouse longevity work used about 100 micrograms/kg (2.5 micrograms per mouse) on 5 consecutive days each month [5]. The throughline: the research record reports doses for specific experimental purposes, none validated for, or applicable to, human self-use. ## DSIP peptide nasal spray Interest in a DSIP peptide nasal spray comes from the intranasal route used in rodent neuroprotection research, where 120 micrograms/kg was delivered nasally — a route chosen to bypass the bloodstream and the peptide's rapid enzymatic breakdown. It is worth being precise: that intranasal work is preclinical and aimed at neuroprotection, not a validated sleep delivery method, and no nasal-spray product has any regulatory approval or established human dose. The peripheral routes with actual human data are intravenous [2]; subcutaneous data comes from cats [10]. A nasal route is a research delivery strategy, not an established way to use DSIP. ## Half-life, routes, and stability DSIP's pharmacokinetics are defined by how fast it disappears. An enzyme-immunoassay clearance study in dogs, monkeys, and rats reported plasma half-lives on the order of only a few minutes, attributed to rapid degradation by aminopeptidases and plasma proteins — and no validated human pharmacokinetic profile exists. Routes used across the literature span intravenous (human and animal), intracerebroventricular (rodent), subcutaneous (cat [10], mouse), intranasal (rat neuroprotection), and in-vitro perifusion. As a short peptide, DSIP is subject to rapid enzymatic breakdown; the phosphorylated analog DSIP-P and other synthetic analogs are reported as more stable or potent in some assays [11]. There is no pharmaceutical-grade product and no stability standard — research material is typically lyophilized and reconstituted for laboratory use only. ## Why there is no human dose The bottom line on DSIP dosage is that a human dose does not exist in any validated sense. The human evidence is confined to small, mostly 1980s pilot trials using 25 nmol/kg intravenously [2][7]; several later human neuroendocrine studies failed to reproduce DSIP's effects on growth hormone, prolactin, ACTH, or cortisol. There is no large randomized controlled trial, no validated human pharmacokinetics, no dosing standard, and no regulatory approval for any indication [3]. The figures on this page are a record of what researchers administered in specific experiments — nothing here should be read as a recommendation. --- A data-forward digest of the delta sleep-inducing peptide literature — every figure sourced, every gap named, and no clinic, vendor, or prescription behind the numbers.